S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
Buy THIS stock before Taiwan is attacked (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Buy THIS stock before Taiwan is attacked (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
Buy THIS stock before Taiwan is attacked (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Buy THIS stock before Taiwan is attacked (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
Buy THIS stock before Taiwan is attacked (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Buy THIS stock before Taiwan is attacked (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
Buy THIS stock before Taiwan is attacked (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Buy THIS stock before Taiwan is attacked (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
NASDAQ:AKYA

Akoya Biosciences - AKYA Stock Forecast, Price & News

$8.18
+0.05 (+0.62%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$8.14
$8.45
50-Day Range
$7.60
$12.68
52-Week Range
$7.20
$16.57
Volume
75,444 shs
Average Volume
159,118 shs
Market Capitalization
$313.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.17

Akoya Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
97.6% Upside
$16.17 Price Target
Short Interest
Bearish
4.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.77) to ($1.52) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Medical Sector

842nd out of 996 stocks

Analytical Instruments Industry

24th out of 29 stocks


AKYA stock logo

About Akoya Biosciences (NASDAQ:AKYA) Stock

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Receive AKYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akoya Biosciences and its competitors with MarketBeat's FREE daily newsletter.

AKYA Stock News Headlines

Stephens Remains a Buy on Akoya Biosciences (AKYA)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.
Akoya Biosciences Announces Leadership Transition
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.
Q4 2022 Akoya Biosciences Inc Earnings Call
See More Headlines
Receive AKYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akoya Biosciences and its competitors with MarketBeat's FREE daily newsletter.

AKYA Company Calendar

Last Earnings
3/06/2023
Today
4/02/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKYA
Fax
N/A
Employees
319
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.17
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+97.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-70,640,000.00
Pretax Margin
-94.20%

Debt

Sales & Book Value

Annual Sales
$74.86 million
Book Value
$1.54 per share

Miscellaneous

Free Float
34,815,000
Market Cap
$313.62 million
Optionable
Not Optionable
Beta
1.08

Key Executives

  • Mr. Brian McKelligon (Age 53)
    Pres, CEO & Director
    Comp: $566.93k
  • Dr. Garry P. Nolan Ph.D. (Age 60)
    Co-Founder, Independent Director & Head of the Scientific Advisory Board
    Comp: $22.5k
  • Mr. Joseph S. Driscoll (Age 57)
    Chief Financial Officer
    Comp: $467.98k
  • Dr. Frederic G. Pla Ph.D. (Age 63)
    Chief Operating Officer
    Comp: $445.27k
  • Dr. Nikolay Samusik Ph.D.
    Co-Founder
  • Dr. Yury Goltsev Ph.D.
    Co-Founder
  • Mr. Clifford C. Hoyt
    VP of Translational & Scientific Affairs
  • Priyam Shah
    Sr. Director of Bus. Devel. & Investor Relations Strategy
  • Mr. Paul Grass
    Sr. VP of Sales
  • Ms. Marilee Moy M.B.A. (Age 63)
    Chief People Officer













AKYA Stock - Frequently Asked Questions

Should I buy or sell Akoya Biosciences stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akoya Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AKYA shares.
View AKYA analyst ratings
or view top-rated stocks.

What is Akoya Biosciences' stock price forecast for 2023?

6 Wall Street research analysts have issued 1 year target prices for Akoya Biosciences' stock. Their AKYA share price forecasts range from $13.00 to $19.00. On average, they anticipate the company's stock price to reach $16.17 in the next year. This suggests a possible upside of 97.6% from the stock's current price.
View analysts price targets for AKYA
or view top-rated stocks among Wall Street analysts.

How have AKYA shares performed in 2023?

Akoya Biosciences' stock was trading at $9.57 at the beginning of 2023. Since then, AKYA stock has decreased by 14.5% and is now trading at $8.18.
View the best growth stocks for 2023 here
.

Are investors shorting Akoya Biosciences?

Akoya Biosciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 722,700 shares, an increase of 45.1% from the February 28th total of 498,000 shares. Based on an average daily trading volume, of 131,100 shares, the short-interest ratio is currently 5.5 days. Currently, 4.3% of the shares of the stock are sold short.
View Akoya Biosciences' Short Interest
.

When is Akoya Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our AKYA earnings forecast
.

How were Akoya Biosciences' earnings last quarter?

Akoya Biosciences, Inc. (NASDAQ:AKYA) posted its earnings results on Monday, March, 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.09. The company had revenue of $21.22 million for the quarter, compared to analysts' expectations of $20.85 million. Akoya Biosciences had a negative trailing twelve-month return on equity of 85.35% and a negative net margin of 94.36%. During the same period in the previous year, the company posted ($0.47) earnings per share.

What ETFs hold Akoya Biosciences' stock?

ETFs with the largest weight of Akoya Biosciences (NASDAQ:AKYA) stock in their portfolio include Principal Healthcare Innovators ETF (BTEC).

What guidance has Akoya Biosciences issued on next quarter's earnings?

Akoya Biosciences issued an update on its FY 2023 earnings guidance on Monday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $95.00 million-$98.00 million, compared to the consensus revenue estimate of $93.08 million.

When did Akoya Biosciences IPO?

(AKYA) raised $125 million in an IPO on Friday, April 16th 2021. The company issued 6,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity acted as the underwriters for the IPO.

What is Akoya Biosciences' stock symbol?

Akoya Biosciences trades on the NASDAQ under the ticker symbol "AKYA."

How do I buy shares of Akoya Biosciences?

Shares of AKYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akoya Biosciences' stock price today?

One share of AKYA stock can currently be purchased for approximately $8.18.

How much money does Akoya Biosciences make?

Akoya Biosciences (NASDAQ:AKYA) has a market capitalization of $313.62 million and generates $74.86 million in revenue each year. The company earns $-70,640,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.

How many employees does Akoya Biosciences have?

The company employs 319 workers across the globe.

How can I contact Akoya Biosciences?

The official website for the company is www.akoyabio.com. The company can be reached via phone at 855-896-8401 or via email at investors@akoyabio.com.

This page (NASDAQ:AKYA) was last updated on 4/2/2023 by MarketBeat.com Staff